257 related articles for article (PubMed ID: 30885273)
1. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
[TBL] [Abstract][Full Text] [Related]
2. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
3. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
4. Dual-specificity tyrosine phosphorylation-regulated kinase 1A promotes the inclusion of amyloid precursor protein exon 7.
Chu D; Lei L; Gu S; Liu F; Wu F
Biochem Pharmacol; 2024 Jun; 224():116233. PubMed ID: 38663682
[TBL] [Abstract][Full Text] [Related]
5. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
6. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
7. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
[TBL] [Abstract][Full Text] [Related]
8. Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.
Ryu YS; Park SY; Jung MS; Yoon SH; Kwen MY; Lee SY; Choi SH; Radnaabazar C; Kim MK; Kim H; Kim K; Song WJ; Chung SH
J Neurochem; 2010 Nov; 115(3):574-84. PubMed ID: 20456003
[TBL] [Abstract][Full Text] [Related]
9. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
10. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.
Liu HL; Zhao G; Zhang H; Shi LD
Behav Brain Res; 2013 Nov; 256():261-72. PubMed ID: 23968591
[TBL] [Abstract][Full Text] [Related]
11. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Jin N; Yin X; Gu J; Zhang X; Shi J; Qian W; Ji Y; Cao M; Gu X; Ding F; Iqbal K; Gong CX; Liu F
J Biol Chem; 2015 Jun; 290(24):15219-37. PubMed ID: 25918155
[TBL] [Abstract][Full Text] [Related]
12. Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling.
Li L; Wu XH; Zhao XJ; Xu L; Pan CL; Zhang ZY
J Neuroinflammation; 2020 Feb; 17(1):61. PubMed ID: 32066466
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
[TBL] [Abstract][Full Text] [Related]
14. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
15. Glucose tolerance and insulin sensitivity are impaired in APP/PS1 transgenic mice prior to amyloid plaque pathogenesis and cognitive decline.
Macklin L; Griffith CM; Cai Y; Rose GM; Yan XX; Patrylo PR
Exp Gerontol; 2017 Feb; 88():9-18. PubMed ID: 28025127
[TBL] [Abstract][Full Text] [Related]
16. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
[TBL] [Abstract][Full Text] [Related]
17. Ca
Yu Z; Dou F; Wang Y; Hou L; Chen H
J Neuroinflammation; 2018 Nov; 15(1):316. PubMed ID: 30442153
[TBL] [Abstract][Full Text] [Related]
18. Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice.
Cui YQ; Wang Q; Zhang DM; Wang JY; Xiao B; Zheng Y; Wang XM
Curr Alzheimer Res; 2016; 13(3):288-96. PubMed ID: 26906357
[TBL] [Abstract][Full Text] [Related]
19. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Proteolytic Pathways and Altered Protein Biosynthesis Underlie Retinal Pathology in a Mouse Model of Alzheimer's Disease.
Mirzaei M; Pushpitha K; Deng L; Chitranshi N; Gupta V; Rajput R; Mangani AB; Dheer Y; Godinez A; McKay MJ; Kamath K; Pascovici D; Wu JX; Salekdeh GH; Karl T; Haynes PA; Graham SL; Gupta VK
Mol Neurobiol; 2019 Sep; 56(9):6017-6034. PubMed ID: 30707393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
